Literature DB >> 17065631

Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms.

G A Pankuch1, P C Appelbaum.   

Abstract

The in vitro postantibiotic effects (PAEs), postantibiotic sub-MIC effects (PA-SMEs), and sub-MIC effects of ceftobiprole were determined for 12 gram-positive organisms. Pneumococcal, staphylococcal, and enterococcal PAEs were 1.4 to 3.1 h, 0 to 1.8 h, and 0 to 0.9 h, respectively. The PA-SMEs (0.4 times the MIC) for pneumococci, staphylococci, and enterococci were 4.8 to >10.3 h, 1.5 to 9.6 h, and 3.8 to >10.7 h, respectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065631      PMCID: PMC1635207          DOI: 10.1128/AAC.00724-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics.

Authors:  J W Mouton; N Punt
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

2.  Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Michael Schleimer; Jill Sauer; Anthony Man; Norman Nashed; Thomas Brown; Antonio Perez; Erhard Weidekamm; Péter Kovács
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

3.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 4.  The post-antibiotic effect.

Authors:  F M MacKenzie; I M Gould
Journal:  J Antimicrob Chemother       Date:  1993-10       Impact factor: 5.790

Review 5.  The post-antibiotic sub-MIC effect in vitro and in vivo.

Authors:  O Cars; I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

6.  In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Authors:  P Hebeisen; I Heinze-Krauss; P Angehrn; P Hohl; M G Page; R L Then
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.

Authors:  Klaudia Kosowska; Dianne B Hoellman; Gengrong Lin; Catherine Clark; Kim Credito; Pamela McGhee; Bonifacio Dewasse; Bülent Bozdogan; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

8.  Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

Authors:  I Odenholt-Tornqvist
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

Review 9.  Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens.

Authors:  W Craig
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

10.  Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

  10 in total
  11 in total

1.  Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus.

Authors:  Jun Taek Oh; Cara Cassino; Raymond Schuch
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Postantibiotic effect of tigecycline against 14 gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-12-08       Impact factor: 5.191

3.  Postantibiotic effects of telavancin against 16 gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

Review 4.  Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

5.  Postantibiotic effect of ceftaroline against gram-positive organisms.

Authors:  G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

6.  Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.

Authors:  April Barbour; Hartmut Derendorf
Journal:  Ther Clin Risk Manag       Date:  2010-10-05       Impact factor: 2.423

7.  Emerging agents to combat complicated and resistant infections: focus on ceftobiprole.

Authors:  César Bustos; Jose L Del Pozo
Journal:  Infect Drug Resist       Date:  2010-04-22       Impact factor: 4.003

Review 8.  Ceftobiprole for the treatment of pneumonia: a European perspective.

Authors:  Adamantia Liapikou; Catia Cillóniz; Antonio Torres
Journal:  Drug Des Devel Ther       Date:  2015-08-18       Impact factor: 4.162

9.  History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.

Authors:  Joseph F John; Alexander M Harvin
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

10.  Postantibiotic effects and postantibiotic sub-MIC effects of tilmicosin, erythromycin and tiamulin on erythromycin-resistant Streptococcus suis.

Authors:  Liping Wang; Yuanshu Zhang
Journal:  Braz J Microbiol       Date:  2009-12-01       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.